Anavex Life Sciences (NASDAQ:AVXL) Announces Quarterly Earnings Results

Anavex Life Sciences (NASDAQ:AVXL) announced its earnings results on Tuesday. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03, Zacks reports. During the same period in the prior year, the business earned ($0.13) earnings per share.

Anavex Life Sciences Stock Down 4.5%

Shares of NASDAQ AVXL traded down $0.39 during trading hours on Tuesday, hitting $8.17. 255,040 shares of the stock were exchanged, compared to its average volume of 1,219,311. Anavex Life Sciences has a 12 month low of $3.51 and a 12 month high of $14.44. The company has a market cap of $697.06 million, a PE ratio of -14.85 and a beta of 0.82. The firm has a fifty day moving average price of $8.93 and a 200-day moving average price of $9.06.

Wall Street Analyst Weigh In

AVXL has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a research note on Monday, April 7th. D. Boral Capital reissued a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.